As gene therapy trials for CHM are undertaken (http://www.ClinicalTrials.gov #NCT01461213, #NCT02077361, and #NCT02341807), we need accurate descriptions of the anticipated change in visual function over time observed in a CHM patient population with confirmed CHM mutations. This evidence concerns the gene CHM and choroideremia.